SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses

Raymond T. Suhandynata, Nicholas J. Bevins, Jenny T. Tran, Deli Huang, Melissa A. Hoffman, Kyle Lund, Michael J. Kelner, Ronald W. McLawhon, Steven L. Gonias, David Nemazee, Robert L. Fitzgerald
doi: https://doi.org/10.1101/2021.03.10.21253299

Article Information

doi 
https://doi.org/10.1101/2021.03.10.21253299
History 
  • March 12, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Raymond T. Suhandynata1,
  2. Nicholas J. Bevins1,
  3. Jenny T. Tran2,
  4. Deli Huang2,
  5. Melissa A. Hoffman1,
  6. Kyle Lund1,
  7. Michael J. Kelner1,
  8. Ronald W. McLawhon1,
  9. Steven L. Gonias1,
  10. David Nemazee2 and
  11. Robert L. Fitzgerald1,*
  1. 1Department of Pathology UC San Diego Health, San Diego CA
  2. 2Department of Immunology and Microbiology, The Scripps Research Institution, San Diego, CA
  1. ↵*Address Correspondence to: Robert Fitzgerald (rfitzgerald{at}ucsd.edu)
Back to top
Posted March 12, 2021.
Download PDF

Supplementary Material

Data/Code
Email
SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses
Raymond T. Suhandynata, Nicholas J. Bevins, Jenny T. Tran, Deli Huang, Melissa A. Hoffman, Kyle Lund, Michael J. Kelner, Ronald W. McLawhon, Steven L. Gonias, David Nemazee, Robert L. Fitzgerald
medRxiv 2021.03.10.21253299; doi: https://doi.org/10.1101/2021.03.10.21253299
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area